Shionogi President Expects Strong Growth On Synergy Effect With Sciele
This article was originally published in PharmAsia News
Executive Summary
Shionogi President Isao Teshirogi expects a strong growth after 2009 when a full synergy effect from acquiring U.S. company Sciele Pharma will take place. Teshirogi expressed the view at a Nov. 4 press briefing to announce interim results. The company has established a U.S. sales network through the ¥155 billion deal, and it also started operations in U.S. and European markets. Regarding U.S. clinic trials for Shionogi's obesity drug S-2367, Teshirogi commented that the results could be announced early next year. Teshirogi also touched upon recent rapid appreciation of yen, he said it is unlikely that the currency appreciation will help reduce research and development expenses in the U.S. (Click here for more - Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.